secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2026-06-26T12:43:39+00:00
Accession:  0001104659-26-078023
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex shareholders OK 3.4M share increase to equity plan; all directors re-elected
--------------------------------------------------------------------------------

- Approved 2021 Omnibus Equity Incentive Plan amendment raising share reserve by 3.4M to 12.9M shares.
- All nine director nominees elected, including CEO Anthony Marucci and Chair Harry Penner Jr.
- Ratification of PwC as independent auditor for FY 2026 passed with 64.7M for vs 174.7K against.
- Advisory say-on-pay proposal approved: 59.2M for, 945K against, 479.7K abstain.
- Plan amendment also clarifies tax withholding provisions for equity awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465926078023/0001104659-26-078023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465926078023/tm2619009d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer